We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make u... Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit. Show more
Zoetis Inc. (NYSE:ZTS) will participate in the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024. Wetteny Joseph, Executive Vice President and Chief Financial Officer...
New Commercial Organizational Structure to Accelerate Long-Term Growth Strategy in Key Markets and Optimize Global Commercial Operations Zoetis Inc. (NYSE:ZTS) today announced the appointment of...
Zoetis Inc. (NYSE:ZTS) will participate in the Jefferies London Healthcare Conference on Wednesday, November 20, 2024. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will...
Reports Revenue of $2.4 Billion, Growing 11%, and Net Income of $682 Million, or $1.50 per Diluted Share, Increasing 14% and 16%, Respectively, on a Reported Basis for Third Quarter 2024...
U.S. index futures rose slightly in pre-market trading on Monday as investors focused on the presidential election and the Federal Reserve’s rate decision. Tuesday’s election is seen...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -2.105 | -1.18688506104 | 177.355 | 179.27 | 174.84 | 2780274 | 177.34325181 | CS |
4 | -4.11 | -2.2914808207 | 179.36 | 183.11 | 169.31 | 2995779 | 175.72036808 | CS |
12 | -13.54 | -7.17199004185 | 188.79 | 200.33 | 169.31 | 2200909 | 183.6390733 | CS |
26 | 5.77 | 3.40453150814 | 169.48 | 200.33 | 166.45 | 2133766 | 180.4659749 | CS |
52 | -2.62 | -1.47298588857 | 177.87 | 201.92 | 144.8 | 2466285 | 177.45475143 | CS |
156 | -46.2 | -20.8624971777 | 221.45 | 249.27 | 124.1483 | 2191734 | 175.10313294 | CS |
260 | 53.96 | 44.4884161926 | 121.29 | 249.27 | 90.14 | 2064943 | 168.22112355 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions